MedPath

Comparison the treatment effect of Pioglithazone with Metformin in patients withNon Alcoholic SteatoHepatitis (NASH)

Phase 2
Conditions
Fatty liver.
fatty (change of) liver, not elsewhere classified
Registration Number
IRCT201105026361N1
Lead Sponsor
Vice chancellor for research, Kashan University of Medical Sciences and Health Services
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

All patients with fatty liver disease based on sonography that have Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) more than normal (more than 40). Exclusion criteria: Alcohol consumption; drug induced hepatitis; use of some drugs (corticosteroids, statins); Diabetes mellitus; Chronic viral hepatitis (B,C); Autoimmune hepatitis; Wilson disease; Hemochromatosis; Ischemic heart disease; Heart failure; Liver failure; liver mass; Pregnancy.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath